Kezar Life Sciences, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Kezar Life Sciences filed its Q1 2026 10-Q, detailing financial performance and ongoing merger activities with Aurinia Pharma.
NASDAQ
Kezar Life Sciences is exploring strategic alternatives to maximize stockholder value, following significant clinical program terminations and a 70% workforce reduction.
NASDAQ
Kezar Life Sciences reported a reduced net loss and lower operating expenses for the first half of 2025, driven by a strategic shift to focus on autoimmune hepatitis after terminating a key lupus nephritis trial.
NASDAQ
Kezar Life Sciences reports a net loss of $16.6 million for Q1 2025, shifting focus to autoimmune hepatitis (AIH) program.
NASDAQ
Kezar Life Sciences announced its third quarter 2024 results, including a net loss of $20.3 million, and the termination of its PALIZADE trial for lupus nephritis.
NASDAQ
10-Q: Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Kezar Life Sciences reports a net loss of $43.2 million for the first six months of 2024, while focusing on clinical development of zetomipzomib.
NASDAQ
Kezar Life Sciences reports a net loss of $21.7 million for the first quarter of 2024, with a focus on advancing clinical programs.